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Background: The exact extent of and the mechanism by which trastuzumab causes cardiac side effects are not
completely unravelled. We investigated the (cardiotoxic) side effects of trastuzumab in a relatively large homo-
geneous population.
Methods:Healthymale volunteers (n=54)with a left ventricle ejection fraction (LVEF) N55%were administered
6 mg/kg trastuzumab (n= 46) IV in 90 min in a placebo-controlled, parallel study. Placebo consisted of 0 · 9%
NaCl (n=8). Assessments included body weight, routine and cardiac laboratory markers and serial echocardio-
graphic examinations (8 placebo and 9 trastuzumab treated participants) up to 63 days after dosing. Statistical
analysis was done using repeated measurements of variance.
Findings: Following trastuzumab infusion, ﬂuid retention was observed: mean body weight increased over the
ﬁrst 4 days post-administration with 0 · 4 kg (95%-conﬁdence interval:−0 · 2, 0 · 9, p= 0 · 2261) compared
to placebo, mean haemoglobin concentration decreased with 0 · 3 mM (−0 · 6,−0 · 1; p= 0 · 0043), as did
haematocrit (−0 · 013 L/L [−0 · 024,−0 · 002], p= 0 · 0216), and protein (−2 g/L [−4,−0], p= 0 · 0443)
and albumin (−2 g/L [−3,−1], p b 0 · 0001) concentrations. Elevations in NT-proBNP levels, parallel to the weight
increase, were observed in individual cases, but not on a group level. Troponin-T concentrations did not increase.
The only echocardiographic parameter that changed signiﬁcantly at all studied dose levels was E/A-ratio, a load-
dependent parameter: from 1 · 81 (SD 0 · 42) to 1 · 98 (0 · 31) 3–5 days after administration, contrast to placebo
of 0 · 57 (90%-CI: 0 · 21–0 · 93, p = 0 · 0034). Ejection fraction and pulsed-wave Doppler recorded parameters
remained unchanged.
Interpretation: Single dose administration of trastuzumab in humans is associated with an immediate, transient extra-
cellular volume increase, either as a primary or secondary (compensatory) response, which can be detected easily
using routine clinical assessments. Echocardiographic changes, both short and long term, couldnot be foundafter single
dose administration to drug-naive patients.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Trastuzumab (Herceptin®) is widely and successfully used in the
treatment of patients with solid tumours overexpressing the human
epidermal growth factor receptor-2 (HER2, also known as ErbB2)
most notably withmamma carcinoma ormetastatic gastric cancer. Not-
withstanding its widespread use in oncology, trastuzumab is feared for
its association with cardiotoxic side effects, occurring in 1–7% of treated
patients, depending on the concomitant and previous chemotherapeu-
tic regimens (Garcia-Alvarez et al., 2010; Seidman et al., 2002).
The exact mechanism by which trastuzumab causes cardiac side
effects is not completely unravelled. Existing evidence suggests that
interaction with the HER2-signalling pathway by trastuzumab insearch, Zernikedreef 8, 2333CL
. This is an open access article undercardiomyocytes, induces apoptosis, and interferes with cell survival
mechanisms (Fuller et al., 2008; Gordon et al., 2009; Riccio et al.,
2009). Compatible with these in vitro ﬁndings, electron microscopy
evaluation of endocardial biopsies from patients who developed
trastuzumab-associated cardiomyopathy showed ultrastructural
changes in the mitochondria (Guarneri et al., 2006). It is, however,
unknown how these ﬁndings translate into clinical practice. The main
reason for this uncertainty is that trastuzumab is often administered
in an adjuvant setting, in combinationwith or after previous use of radi-
ation therapy or cytostatics with untoward cardiac effects, such as
anthracyclines. Furthermore, trastuzumab is used in a heterogeneous
population regardinggender, age, and co-morbidities. Seemingly, therefore,
exploring trastuzumab in a homogenous population of healthy subjects
could be of value to further delineate its cardiac effects and its time.
We recently performed a bio-equivalence trial in which the current-
ly approved formulation of trastuzumab (Herceptin®) was compared
with a trastuzumab drug product under development, code-namedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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serial assessments of echocardiographic measurements, body weight
and laboratory parameters such as the N-terminal pro-peptide of B-
type natriuretic peptide (NT-proBNP) were included in the trial design,
both to safeguard the participant's well-being and to investigate the
(cardiotoxic) side effects of trastuzumab. The aim of the analysis pre-
sented in this articlewas to compare the registered formof trastuzumab
(Herceptin®)with placebo in healthy volunteers, in terms of the assess-
ments of cardiac function, and thus to cardiotoxicity.
2. Methods
2.1. Study Design and Population
The trialwas a single-centre study of parallel design that consisted of
a placebo-controlled double-blind dose escalation scheme (Fig. 1,
groups 1–4), and an open-label single-dose bio-equivalence part
(Fig. 1, group 5) (Wisman et al., 2014). In total, 118 male volunteers,
aged 18–45 years inclusive, who were deemed healthy after a full
medical screening, were enrolled sequentially in one of ﬁve groups. All
had a left ventricle ejection fraction (LVEF) N55%, measured with
echocardiography. The study was approved by an accredited local
(BEBO, Assen, The Netherlands) and national independent medical
ethics committee (CCMO, The Hague, The Netherlands), and registered
under NL37452·056·11/EudraCT 2011-002972-17. Each participant
provided written informed consent.
Participants randomly received either placebo (250mL 0 · 9% NaCl)
or trastuzumab in 250 mL 0 · 9% NaCl, administered intravenously in
90 min. Two trastuzumab drug products were investigated: the regis-
tered form (Herceptin®) at a dose of 6mg/kg (n=46), and a biosimilar1 2 3
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Fig. 1. Participant ﬂow diagram. Flow of participants: enrolment was sequential in one of ﬁve
laboratory results and bodyweight data were available for groups 2–5. Cohorts markedwith an
ysis on the extended dataset (see main body). BS biosimilar product of trastuzumab.form, codenamed FTMB, in escalating doses of 0 · 5–6 mg/kg (n= 64).
For the purpose of assessing the cardiac effects of trastuzumab, only par-
ticipantswho received the registered formof trastuzumab (Herceptin®,
hereafter referred to as “trastuzumab”) or placebo were analysed.
2.2. Randomisation and Masking
All participants were assigned a unique number. Study medication
was dispensed by a pharmacist according to a pre-established computer
generated sequence, prepared using SAS® (v9·1·3, SAS Institute Inc.,
Cary, NC, USA) by a statistician, both of whom were not involved in
the clinical conduct of the study. Concealment of treatment allocation
was thus implemented. Placebo and trastuzumab treatment looked
alike.
2.3. Laboratory Assessments and Body Weight
At baseline and at 1, 2, 4, 8 and 63 ± 7 days post-treatment, body
weight was determined on a calibrated scale and samples for routine
clinical chemistry and haematology were collected. An additional sam-
ple for troponin-T andNT-proBNP onlywas taken at 8 h post-dose. Sam-
ples were analysed by the clinical laboratories of the Leiden University
Medical Center (LUMC). The measured laboratory parameters included
electrolytes, liver panel, urea, creatinine, albumin, total protein, lipid
spectrum, complete blood count and leukocyte differential, troponin-
T, and NT-proBNP (N-terminal pro-peptide of B-type natriuretic
peptide).
Measurement of bodyweight in the follow-up period and laboratory
assessments at 8 h and at 1, 2, and 8 days post-administration were in-
corporated in the clinical trial protocol with an amendment after the4 5
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groups (see main body); echocardiographic examinations were available for groups 1–4,
asterisk were not analysed, although baseline effects were included in the secondary anal-
Table 1
Baseline characteristics.
Parameter All* (n= 110) Trastuzumab
(n= 46)
Placebo
(n= 6)
Demographics
Age (year) 25.4 (6.7) 24.1 (5.8) 24.8 (3.1)
Body weight (kg) 77.2 (10.4) 76.9 (10.2) 72.5 (6.1)
Routine clinical haematology and
chemistry
Erythrocytes (1012 L−1) 4.98 (0.35) 5.01 (0.41) 5.04 (0.18)
Thrombocytes (109 L−1) 219 (43) 220 (38) 244 (41)
Haemoglobin (mM) 9.2 (0.5) 9.1 (0.5) 9.6 (0.4)
Haematocrit (L/L) 0.435 (0.0220) 0.434 (0.021) 0.446 (0.0196)
Total protein (g L−1) 71.1 (3.6) 70.9 (3.7) 72.8 (4.1)
Albumin (g L−1) 46.4 (2.2) 46.3 (2.0) 48.5 (2.8)
Creatinine (μM) 76.7 (9.5) 77.0 (9.7) 78.8 (8.5)
Cardiac biomarkers
NT-proBNP (ng L−1) 12.1 (14.5) 11.6 (14.3) 3.0 (0.0)
NT-proBNP b LOQ (n) 51 (46.4%) 20 (43.5%) 6 (100.0%)
Troponin-T b LOQ (n) 102 (92.7%) 42 (91.3%) 5 (83.3%)
Parameter All* (n= 44) Trastuzumab
(n= 9)
Placebo
(n= 8)
Echocardiography
LVEF (%) 67.9 (5.7) 67.3 (6.2) 63.8 (4.5)
FS (%) 38.3 (4.7) 37.9 (4.9) 35.0 (3.5)
E/A 1.66 (0.40) 1.81 (0.42) 1.46 (0.33)
DT (ms) 193 (57) 172 (37) 188 (35)
S′ (m s−1) 0.11 (0.03) 0.13 (0.03) 0.12 (0.03)
E′ (m s−1) 0.15 (0.03) 0.16 (0.03) 0.16 (0.04)
TAPSE (cm) 2.4 (0.4) 2.2 (0.3) 2.5 (0.5)
Mean (SD) or number of subjects (percentage). * Including also the baseline values of the
participants receiving the biosimilar product. LVEF left ventricular ejection fraction; FS
fractional shortening; E/A ratio of peak early (E) and late (A) velocities; DT deceleration
time; S′ systolic annular velocity of the lateral wall (pulsed-wave tissue Doppler); E′
early diastolic annular velocity of the lateral wall (pulsed-wave tissue Doppler); and
TAPSE tricuspid annular plane systolic excursion.
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were only available in groups 2–5 (Fig. 1).
2.4. Echocardiography
Echocardiographywas performed at the department of cardiology of
the LUMC by trained laboratory technicians using an E-9 system (GE
Healthcare, Horten, Norway) under responsibility of a cardiologist
(blinded to the treatment). Two-dimensional, colour, continuous and
pulsed-wave Doppler images were acquired in the parasternal and api-
cal views. The acquiredmeasurements were speciﬁed in a separate pro-
tocol, and focused on obtaining information on the global systolic and
diastolic left ventricular function. From parasternal M-mode recordings,
left ventricular ejection fraction (LVEF) and fractional shortening (FS)
were measured. Additionally, from the pulsed-wave Doppler spectral
signal of the mitral inﬂow acquired in the apical 4-chamber views the
peak early (E) and late (A) velocities and deceleration time (DT) of
the Ewaveweremeasured and the E/A-ratio was derived. Furthermore,
from pulsed-wave tissue Doppler recordings obtained at the level of the
left ventricular lateral wall the systolic annular velocity of the lateral
wall (S′, TDI) and early diastolic annular velocity of the lateral wall (E′,
TDI) were measured. Finally, right ventricular systolic function was
assessed by means of tricuspid annular plane systolic excursion
(TAPSE).
All participants underwent echocardiographic examination at
screening (within 21 days of trial drug administration). Follow-up
examinations were performed at 4 ± 1 and 63 ± 14 days post-dose in
the ﬁrst part of the trial (Fig. 1, groups 1–4), including all placebo partic-
ipants and 9 participants receiving trastuzumab.
2.5. Statistical Analysis
The trial was powered on the bio-equivalence (pharmacokinetic)
endpoint; however, the calculated sample size of 46 participants in
the trastuzumab arm, and 8 placebo subjects was deemed sufﬁcient to
detect clinically relevant hemodynamic changes.
Individual time proﬁles and treatment group averages were studied
for all assessed parameters. Treatment groups were compared using
mixed effect analyses of variance. This analysis incorporated participant
as random factor, treatment as ﬁxed factor, and as covariates baseline
value and age. Time and treatment by time were included as well, in
case of repeated measurement comparison. Contrasts and effects
(with 95%-conﬁdence intervals) were calculated as relevant.
A second analysis was performed which included the baseline ef-
fects of the participants who were exposed to the biosimilar product
(Fig. 1), thereby allowing the model to more precisely estimate and
separate inter- and intra-individual variation from treatment effects,
in order to approximate the true population more closely, diminishing
the likelihood that certain signiﬁcant ﬁndings are the result of chance.
Since the observed changes in laboratory parameters were quite
variable between individuals, with the time atwhich themaximal effect
was reached ranging from1 to 4 days post-dose, it was decided to calcu-
late the area under the curve (AUC) for each parameter to integrate the
effects over time. AUCs were calculated on actual and on baseline-
normalised values (respectively AUC and AUCcfb hereafter), using the
linear trapezoidal method. Mean AUC, deﬁned as AUC divided by the
delta time component and denoted mAUC and mAUCcfb respectively,
served as a measure of the average post-treatment value — or average
change from baseline, in case of mAUCcfb. Unless otherwise speciﬁed,
hereafter, mAUC and mAUCcfb relate to the AUC at 4 days post-
administration.
Values below the limit of quantiﬁcation (LOQ, 0 · 003 μg/L for
troponin-T and 5 ng/L for NT-proBNP) were inputted as 0 · 002 μg/L
and 3 ng/L respectively. Missing baseline observations were replaced
with the corresponding screening values (≤21 days before baseline).Echocardiographic examinations not occurring on the scheduled day
were excluded from analysis. To meet the assumption of normal distri-
bution, LVEF, FS, DT, and TAPSE values were ln-transformed prior to
statistical analysis.
Descriptive statistics and graphswere produced using R (v2·15·2, R
Foundation for Statistical Computing, Vienna, Austria, 2012 [R Develop-
ment Core Team, 2012]), and statistical analyses were performed with
SAS® (v9·1·3, SAS Institute Inc., Cary, NC, USA). Results are presented
asmean (standard deviation or 95% conﬁdence interval) for continuous
data and as number (percentage) for categorical data, unless otherwise
speciﬁed.
2.6. Role of the Funding Source
The bioequivalence trial (Wisman et al., 2014) was funded by
Synthon BV, Nijmegen, The Netherlands; and included the measure-
ments to investigate potential cardiotoxicity and haemodynamic effects
in its design. However, Synthon BV was not involved in the analysis as
described here or in the writing of the manuscript.
3. Results
Between August and November 2011, one hundred eighteen (118)
males were recruited from the community (Fig. 1). The baseline charac-
teristics are presented in Table 1.
From all participants, who received placebo or trastuzumab (Fig. 1),
261 routine chemistry and haematology follow-up observations were
included in the analysis, as well as 30 follow-up echocardiographic ex-
aminations, 259 body weights, and 316 measurements for NT-proBNP
(137 b LOQ) and Troponin-T (287 b LOQ) levels. No baseline result
was missing.
Table 2
Results: body weight and laboratory parameters.
Parameter Trastuzumab (n= 46) Placebo (n= 6)
Body weight (kg) 0.7 (0.6) 0.3 (0.9)
Erythrocytes (1012 L−1) −0.09 (0.15) 0.04 (0.13)
Thrombocytes (109 L−1) −3 (13) 7 (14)
Haemoglobin (mM) −0.2 (0.3) 0.1 (0.2)
Haematocrit (L/L) −0.007 (0.013) 0.003 (0.010)
Total protein (g L−1) −0.1 (2.6) 1.1 (1.8)
Albumin (g L−1) −0.3 (1.7) 0.6 (1.6)
Creatinine (μM) 2.5 (3.6) −0.3 (3.6)
NT-proBNP (ng L−1) 4.1 (10.3) 3.7 (6.2)
Mean (SD) of the average change from baseline at 4 days post-administration (mAUCcfb).
Table 3
Analysis of variance: body weight and laboratory parameters.
Contrast
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during the entire follow-up period; and in the remaining participants,
changes post-treatment could not be observed. Troponin-T results
were therefore not analysed statistically. For NT-proBNP, the corre-
sponding number was 4/52 (7 · 7%) participants, of whom 3/6 in the
placebo group.
The time course of a selection of parameters after infusion of 6mg/kg
Herceptin® in a 22 year old healthy male is depicted in Fig. 2. A clear
decline in erythrocyte concentration (and related parameters, like
haemoglobin and haematocrit) characterises the ﬁrst 2–4 days post-ad-
ministration, with a return to baseline between 8 and 63 days post-
dose. This decline was paralleled by a decrease in protein and albumin
concentration, whereas body weight and NT-proBNP level increased.
Tables 2 and 3 present the results of selected laboratory parameters
and body weight at 4 days post-administration. Compared to placebo,
the haematocrit decreased on average with 0 · 013 L/L (mAUC,
p≈ 0 · 02) as did the erythrocyte, thrombocyte, and haemoglobin con-
centrations (Fig. 3). Similarly, the total protein and albumin concentra-
tions declined, with a difference in mAUC of 2 g/L between placebo and
trastuzumab. These differenceswere statistically signiﬁcant (p b 0 · 05),
with the exception of the creatinine and erythrocyte concentrations.
Body weight increased with 0 · 7 (0 · 6) kg (Fig. 3), although com-
pared to placebo the difference was less, mAUC 0 · 4 kg (−0 · 2–
0 · 9, p≈ 0 · 2, Table 3), most likely due to 2/6 placebo subjects who
steadily increased in body weight N3 kg from baseline to 63 days
post-dose, without changes in laboratory parameters. Creatinine con-
centration and NT-proBNP did not differ signiﬁcantly from placebo.
The total protein time proﬁle (Fig. 3) seems to suggest that the
difference between the trastuzumab group and placebo is solely attrib-
utable to an absolute change from baseline in the placebo group. Inter-
estingly, however, at 8 days post-administration the total protein
concentration in both groups had increased in a comparable fashion.
The protein concentration-time proﬁle in the trastuzumab group was
thus characterised by a minor decrease and/or lag time of multiple
days before increasing, whereas the proﬁle in the placebo group could
be described by a linear increase. Albumin and thrombocyte concentra-
tions displayed a similar phenomenon of a minor decrease and/or lag
time in the trastuzumab group.Time post administration (day)
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Fig. 2. Time proﬁle. Time proﬁles of safety parameters in a 22 year old healthy male, who
received 6 mg/kg trastuzumab.Clinically signiﬁcant changes or trends on either individual or group
level could not be discerned for any of the other laboratory parameters.
All participants had returned to baseline by either 8 or 63±7 days post-
treatment (Fig. 3).
Treatment effects on the echocardiographic parameters were less
straightforward (Table 4). The LVEF increased relatively by 1 · 9% com-
pared to placebo. Fractional shortening (FS) followed the LVEF closely.
The deceleration time (DT) and TAPSE values increasedwith ameandif-
ference versus placebo of respectively 31 · 0% and 9 · 9%,whereas S′ and
E′ values remained stable (Fig. 4).
The only echocardiographic parameter that changed signiﬁcantly
was the E/A-ratio, which differed from placebo 0 · 57 (0 · 21–0 · 93,
p= 0 · 0034) at 3–5 days post-dose.
In the analysis on the extended dataset, including also the baseline
effects of participants who received the biosimilar product, all contrasts
between trastuzumab and placebo remained virtually unaltered
(Tables 3 and 4), with the exception of the contrast for DT. Probably
the baseline variability on this parameter was greater in the entire
study population than in the trastuzumab arm (Table 1). TreatmentParameter Analysis 1 Analysis 2a
Body weight (kg) 0.4
(−0.2, 0.9)
p= 0.2261
0.4
(−0.2, 0.9)
p= 0.1885
Erythrocytes (1012 L−1) −0.12
(−0.25, 0.01)
p= 0.0720
−0.12
(−0.25, 0.01)
p= 0.0726
Thrombocytes (109 L−1) −11
(−23, 0)
p= 0.0524
−11
(−22,−1)
p= 0.0348
Haemoglobin (mM) −0.3
(−0.6,−0.1)
p= 0.0043
−0.4
(−0.6,−0.1)
p= 0.0014
Haematocrit (L/L) −0.013
(−0.024,−0.002)
p= 0.0216
−0.013
(−0.023,−0.002)
p= 0.0168
Total protein (g L−1) −2
(−4,−0)
p= 0.0443
−2
(−4,−0)
p= 0.0462
Albumin (g L−1) −2
(−3,−1)
p b 0.0001
−2
(−3,−1)
p= 0.0011
Creatinine (μM) 2.5
(−0.4, 5.4)
p= 0.0943
2.4
(−0.6, 5.5)
p= 0.1148
NT-proBNP (ng L−1) 2.8
(−5.5, 11.1)
p= 0.5029
3.0
(−5.7, 11.8)
p= 0.4932
Contrasts (95% conﬁdence intervals) and p-values of average values (mAUCs) at 4 days
post-administration, comparing trastuzumab to placebo. The analysis of variance corrects
for baseline effects (see main body).
a Secondary analysis of variance on an extended dataset, including also the baseline
effects of the participants receiving the biosimilar product (see main body).
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Table 4
Analysis of variance: echocardiographic parameters.
Contrast
Parameter Analysis 1 Analysis 2a
LVEF* 1.9
(−7.1, 11.8)
p= 0.6722
1.6
(−4.8, 8.5)
p= 0.6213
FS* 1.8
(−10.5, 15.8)
p= 0.7714
2.0
(−6.8, 11.7)
p= 0.6611
E/A 0.57
(0.21, 0.93)
p= 0.0034
0.50
(0.10, 0.90)
p= 0.0146
DT* 31.0
(3.6, 65.7)
p= 0.0261
16.0
(−10.4, 50.2)
p= 0.2560
S′ (m/s) 0.00
(−0.03, 0.03)
p= 0.8352
0.00
(−0.02, 0.03)
p= 0.8033
E′ (m/s) 0.02
(−0.02, 0.06)
p= 0.2862
0.02
(−0.01, 0.05)
p= 0.2415
TAPSE* 9.9
(−7.5, 30.6)
p= 0.2640
9.0
(−6.1, 26.4)
p= 0.2519
Contrasts (95% conﬁdence intervals) and p-values of echocardiographic parameters at day
4 ± 1 post-administration, comparing trastuzumab to placebo. The analysis of variance
corrects for baseline effects (see main body). Parameters marked with an asterisk were
ln-transformed prior to analysis; their contrasts are back-transformed and presented as
percentage.
LVEF left ventricular ejection fraction; FS fractional shortening; E/A ratio of peak early
(E) and late (A) velocities; DT deceleration time; S′ systolic annular velocity of the lateral
wall (pulsed-wave tissue Doppler); E′ early diastolic annular velocity of the lateral wall
(pulsed-wave tissue Doppler); and TAPSE tricuspid annular plane systolic excursion.
a Secondary analysis of variance on an extended dataset, including also the baseline
effects of the participants receiving the biosimilar product (see main body).
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TAPSE) also became less pronounced.
Age inﬂuenced the results signiﬁcantly only for DT (effect −0.
0255ms [−0 · 0443,−0 · 0067] per annum, p=0 · 0122). In the anal-
ysis on the extended dataset the age effect on DT disappeared, whereas
a signiﬁcant age effect was detected on E′ (effect −0 · 0021 m/s
[−0 · 0036,−0 · 007] per annum, p= 0 · 0051). However, excluding
this covariate did not improve the model, or modify the results of the
analysis signiﬁcantly.
4. Discussion
This is the ﬁrst report of effects of trastuzumab on the cardiac func-
tion in a homogeneous healthy population, as well as the ﬁrst to evalu-
ate these effects during the ﬁrst eight days after administration by
means of routine laboratory and echocardiographic assessments
which are commonly employed in the clinic to monitor patients with
cardiomyopathy.
Fig. 2 captures themain ﬁndings following trastuzumab administra-
tion. The combination of changes, their time-proﬁle, and the absence of
signs of haemolysis or blood loss (other than the per protocol blood col-
lections), indicate that there was haemodilution caused by ﬂuid reten-
tion, given the concomitant increase in body weight. Such a pattern
was noted in many participants treated with trastuzumab, although
on a group level, the effects were less pronounced. Most importantly,
none of these participants experienced cardiac symptoms of any nature
(Wisman et al., 2014).
It is known that the ErbB2-receptor functions as a co-receptor which
heterodimerises with other activated ErbB-class receptors. This
dimerisation process is crucial for the initiation of downstream signal-
ling of all EGF-receptors, but also decreases ligand dissociation as well
as stabilises the dimer, thereby prolonging the activation of the signal-
ling pathway (Fuller et al., 2008).
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stimulates proliferation, contractility and survival of cardiomyocytes
and interference by for example trastuzumab is thought to compromise
anti-apoptotic pathways, which lessens the counterbalance to noxious
stimuli (Fuller et al., 2008; Force et al., 2007; Lemmens et al., 2007).
Our results are in line with these preclinical ﬁndings and indeed con-
ﬁrm, as was suggested by in vitro experiments (Riccio et al., 2009),
that already during the ﬁrst days after trastuzumab administration
haemodynamic effects can be noticed. Obviously, this assumes that
the effect is receptor-mediated, ignoring reports which have implied
other mechanisms of action (Riccio et al., 2009; Force et al., 2007;
Troise et al., 2011).
The observed change in volume status can be explained by an activa-
tion of the renin-angiotensin-aldosterone system (RAAS). Whether or
not this is a secondary (compensatory) response to maintain an
adequate effective circulating volume, or a primary response, caused
by direct interference with ErbB2/ErbB4-signalling by trastuzumab,
cannot be determined based on our results. Interactions between
angiotensin II and ErbB-signalling have been described previously
(Fuller et al., 2008), and this observation further supports treatment of
trastuzumab-associated cardiomyopathy with ACE-inhibitors.
Even though the on averagemodest effects were clearly distinguish-
able for the laboratory parameters, changes in echocardiographic
parameters could not be detected, with the exception of a concise effect
on the E/A-ratio. However, most likely, this observation reﬂects the
changed volume status, and in itself does not indicate clinically relevant
cardiotoxicity. This is in keeping with the ﬁnding that the TDI measure-
ments, which are less load-dependent, remained unchanged.
A substantial and lasting decline in LVEF, as well as other earlier ra-
diographic ﬁndings, generally ﬁrst occur after months of continuoustrastuzumab exposure in a population more predisposed than healthy
volunteers (Fallah-Rad et al., 2011; Morris et al., 2013; Goldhirsch
et al., 2013). Probably, these abnormalities already mark the progres-
sion to chronic heart failure (CHF) after the ‘normal’ compensatory
mechanisms towards trastuzumab's effects have been exhausted. We
hypothesise therefore that monitoring patients in the early days after
trastuzumab treatment with routine laboratory parameters and body
weight measurements, as used in this trial – but also with more
sensitive markers of RAAS-activation, like urinary sodium excretion
and hormone levels – could be valuable in establishing an individual
patient's susceptibility to trastuzumab-induced haemodynamic effects.
Cardiospeciﬁc biomarkers are well recognised as predictors of drug-
induced cardiotoxicity. For example, NT-proBNP elevation is associated
with the development of cardiac dysfunction (Feola et al., 2011; Sandri
et al., 2005), although others could not detect a signiﬁcant change over a
12months treatment periodwith trastuzumab, even in the subset of pa-
tients who developed CHF (Fallah-Rad et al., 2011; Sawaya et al., 2012).
However, many of the trastuzumab reports have focused on long term
effects, and did not include assessments during the ﬁrst days. In individ-
ual cases, a peak in NT-proBNP concentration, coinciding with the
maximal effect in terms of haemodilution and body weight (Fig. 2),
was observed in this study. On a group level, this did not result in a
signiﬁcant difference compared to placebo, probably in consequence
of the small number of participants having detectable NT-proBNP
levels.
Contrary to our results, transient increases in cardiac-speciﬁc tropo-
nin have been observed in 12–50% of patients following trastuzumab
treatment, most frequently after the ﬁrst cycle, and troponin-I was
found to be the strongest independent predictor of cardiotoxicity in
multivariate analyses (Cardinale et al., 2010; Ky et al., 2014; Morris
959J.A.A. Reijers, J. Burggraaf / EBioMedicine 2 (2015) 953–959et al., 2011). However, it should be noted that in these studies
trastuzumab administration was part of a treatment regime which
included cytostatics.
The main strength of this trial lies in the relatively large homoge-
neous population and its randomised, placebo-controlled design. The
fact that only healthy volunteers participated ensured that the results
were not clouded by comorbidities or concomitant and previous
(cardiotoxic) treatments. Furthermore, the used assessments are com-
monly employed to monitor patients with cardiomyopathy, which
makes the ﬁndings easy implementable in clinical practice, without in-
creasing costs.
An important weakness of the analysis is the comparison to a rela-
tively small placebo group, which consisted of six subjects for body
weight and laboratory data. This could potentially skew the placebo
population, obscuring trastuzumab's effects. Because of the placebo
condition as control group, it could also be argued that the observed vol-
ume increase is a non-speciﬁc effect caused by the administration of a
monoclonal antibody. However, experience with intravenous adminis-
tration of (therapeutic) doses of both experimental and registered
monoclonal antibodies in healthy volunteers has revealed neither ele-
vations in body weights nor haemodilution, either in the short or
long-term (data on ﬁle). Interestingly though, increases in total protein
and albumin were observed during the ﬁrst week after administration
in both the placebo and monoclonal antibody arms of those trials,
which is similar to the proﬁles in the placebo treated subjects as
presented in Fig. 3.
In conclusion, the presented results suggest that trastuzumab
administration in humans is associated with an immediate, transient
volume increase, either as a primary (direct) or a secondary (compensa-
tory) response, which can be detected easily using routine clinical
assessments. Echocardiographic changes, both short and long term,
could not be found after single dose administration to drug-naive
patients.
With the arrival of more biosimilars, the future will likely see an in-
crease in relatively large bio-equivalence trials in healthy volunteers.
This offers unique opportunities to evaluate, in a detailed and systemat-
ic fashion, intentional and unintentional effects of existing drugs in a
homogeneous population.Contributors
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